近年來,免疫治療在許多種癌症展現突破性的療效,也成為多種癌症的標準療程之一,其中programmed cell death protein-1(PD-1)抑制劑已是肝癌的二線標準治療藥物。然而,使用PD-1抑制劑後進行器官移植的安全性是目前未知的。本文提出一位晚期肝癌用nivolumab使腫瘤達到完全緩解,但因免疫相關膽管炎而停用nivolumab,並於一年後能成功接受肝臟移植的案例。此案例顯示,在適當時間間隔下,PD-1抑制劑在器官移植前使用是安全的。
Khouri IF, Fernandez Curbelo I, Turturro F, et al. Ipilimumab plus Lenalidomide after Allogeneic and Autologous Stem Cell Transplantation for Patients with Lymphoid Malignancies. Clin Cancer Res 2018;24:1011-8.
Ravandi F, Assi R, Daver N, et al. Idarubicin, cytarabine, and nivolumab in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a single-arm, phase 2 study. Lancet Haematol 2019;6:e480-8.
El Cheikh J, Massoud R, Abudalle I, et al. Nivolumab salvage therapy before or after allogeneic stem cell transplantation in Hodgkin lymphoma. Bone Marrow Transplant 2017;52:1074-7.
Merryman RW, Kim HT, Zinzani PL, et al. Safety and efficacy of allogeneic hematopoietic stem cell transplant after PD-1 blockade in relapsed/refractory lymphoma. Blood 2017;129:1380-8.
Chen, H. Y., Ker, C. G., Juan, C. C., & Lo, H. W. (2000). 腹腔鏡治療肝癌合併肝硬化之肝次葉切除術:病例報告. The Kaohsiung Journal of Medical Sciences, 16(11), 582-586. https://doi.org/10.6452/KJMS.200011.0582
Ho, C. B., Chiou, J. F., Kuo, C. C., Ting, L. L., Chen, S. W., Ch’ang, H. J., & Lee, H. L. (2016). 以放射線及標靶藥物Sorafenib治療肝癌合併下腔靜脈及右心房腫瘤栓塞並達到完全緩解效果的一個案例報告. 放射治療與腫瘤學, 23(3), 205-212. https://doi.org/10.6316/TRO/201623(3)205
Lo, C. H., Huang, W. Y., Chao, H. L., Lin, K. T., Chen, C. M., Yang, J. F., Jhang, J. K., & Lin, C. S. (2017). 併用經導管動脈化學栓塞及立體定位消融放射治療成功治療肝癌病人移植後復發:個案報告. 放射治療與腫瘤學, 24(2), 161-166. https://doi.org/10.6316/TRO/201624(2)161